Glenmark receives USFDA approval to market generic Esomeprazole Magnesium delayed-release capsules, a generic version of Nexium. This approval will allow the company to enter the market for treating conditions caused by excess stomach acid.
New Delhi, Jun 24 (PTI) Drug firm Glenmark on Wednesday said it has received approval from the US health regulator to market a generic medication to treat conditions caused by too much acid production in the stomach.
Glenmark Specialty SA has received final approval from the US Food & Drug Administration (USFDA) for Esomeprazole Magnesium delayed-release capsules, the drug maker said in a statement.
The company's product is the generic version of Haleon US Holdings LLC's Nexium.
According to Nielsen syndicated data for the latest 52-week period ending May 18, 2024, the Nexium24 HR delayed-release capsules (20 mg) achieved annual sales of around USD 259.2 million.
Shares of Glenmark were trading 0.55 per cent down at Rs 1,185 apiece on the BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback